clinical trial · NCT06787950
Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors
Jiangsu Yahong Meditech Co., Ltd aka Asieris·phase2·not yet recruiting·n = 200
Advanced Solid TumorsASN-3186ASN-3186ASN-3186
brief summary
This is a Phase I/IIa, open-label, multi-center, dose-escalation, and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of ASN-3186 when given orally in subjects with advanced solid tumors
started
Feb 20, 2025
primary completion
Mar 20, 2029
completion
Sep 20, 2029
last updated
Jan 22, 2025
official title
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Anti-tumor Activity of ASN-3186 in Patients with Advanced Solid Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol